Taysha Gene Therapies (Taysha Gene Therapies) ROCE % : -76.80% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Taysha Gene Therapies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Taysha Gene Therapies's annualized ROCE % for the quarter that ended in Mar. 2024 was -76.80%.

Taysha Gene Therapies ROCE % Historical Data

The historical data trend for Taysha Gene Therapies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taysha Gene Therapies ROCE % Chart

Taysha Gene Therapies Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-47.68

-83.63

-143.75

-106.86

Taysha Gene Therapies Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial													-117.49	-237.37	-2,001.14	256.21	-76.80

Taysha Gene Therapies ROCE % Calculation

Taysha Gene Therapies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-106.568	/	( ( (126.276 - 62.79)	+	(172.731 - 36.756) )	/ 2 )
	=	-106.568	/	( (63.486	+	135.975)	/ 2 )
	=	-106.568	/	99.7305
	=	-106.86 %

Taysha Gene Therapies's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-96.128	/	( ( (172.731 - 36.756)	+	(152.999 - 38.637) )	/ 2 )
	=	-96.128	/	( ( 135.975	+	114.362 )	/ 2 )
	=	-96.128	/	125.1685
	=	-76.80 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Taysha Gene Therapies (NAS:TSHA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Taysha Gene Therapies ROCE % Related Terms

Thank you for viewing the detailed overview of Taysha Gene Therapies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Taysha Gene Therapies (Taysha Gene Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taysha Gene Therapies Inc (NAS:TSHA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247

Website

https://www.tayshagtx.com

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.

Executives

Paul B Manning	director, 10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Alison S Long	director	KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kamran Alam	officer: Chief Financial Officer	350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
Sean P. Nolan	director	C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Phillip B. Donenberg	director	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Session R.a. Ii	10 percent owner	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Sukumar Nagendran	director	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Astellas Pharma Inc.	10 percent owner	2-5-1, NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-8411
Audentes Therapeutics, Inc.	10 percent owner	600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Suyash Prasad	officer: CMO and Head of R&D	C/O AUDENTES THERAPEUTICS, INC., 101 MONTGOMERY ST., SUITE 2650, SAN FRANCISCO CA 94104
Laura Sepp-lorenzino	director	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Kathleen Reape	director	C/O TAYSHA GENE THERAPIES, INC., 2280 INWOOD ROAD, DALLAS TX 75235